LifeMD Reports Third Quarter 2025 Results
- Total revenue increased 13% year-over-year to $60.2 million, and adjusted EBITDA rose 20% to $5.1 million.
- Telehealth revenue grew 18% to $47.3 million, while telehealth adjusted EBITDA increased 30% to $2.9 million.
- Paid off all outstanding debt during the quarter.
- Subsequent to quarter end, fully divested our majority stake in WorkSimpli, positioning LifeMD as a pure-play telehealth and pharmacy platform.
- Continued to diversify clinical platform with new launches in women’s health, men’s health and psychiatry.